Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Parkinson's drug ease symptoms of a rare childhood brain condition?

NCT ID NCT07614126

Recruiting now Symptom relief Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether L-dopa, a drug used for Parkinson's, can improve movement and communication in children with a rare genetic disorder called CTNNB1 syndrome. The condition causes developmental delays, muscle stiffness, and trouble walking. Seven children aged 1 to 15 will receive L-dopa for 6 to 12 months, and researchers will measure changes in motor skills using a standard scale.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CTNNB1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

CTNNB1-related neurodevelopmental disorder and/or vitreoretinopathy severe intellectual disability-progressive spastic diplegia syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTNNB1 L-DOPA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Montpellier

    RECRUITING

    Montpellier, Hérault, 34295, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••